All times shown in GMT - please see the Full Event Guide for CET

8:30 am Coffee & Registration

9:15 am Chair’s Opening Remarks

9:30 am Updates on FasT CAR Technology to Reduce Cell Therapy Vein-to-Vein Time and Cost

10:00 am Developing Parallel CAR-T for Increased Efficacy

  • John Maher Immunology Consultant, King’s College London / CSO , Leucid Bio

10:30 am Refreshment Break & Networking

Research & Development

Translation

Manufacturing & Commercialisation

Progress in Next-Generation Target Identification

Enhancing CAR-T for Haematological Conditions

Optimising Clinical Development
& Affordability in Europe

11.30 Systemised Cell Biology Approaches Enabling TCR-based Cellular Therapies

To see full session details, download the full event guide

Reagan Jarvis, CEO, Anocca AB

11:30 BCMA as an Ideal Target for Treating
Myeloma and Global Competition in BCMA Targeting Immunotherapies

To see full session details, download the full event guide

Frank Fan, Co-Founder & CSO, Legend Biotech

11.30 Developing European Standards for
Clinical Delivery of Cell Immunotherapies

To see full session details, download the full event guide

Nina Worel, Medical Director of Tissue & Cell Collection & Processing Facility, Medical University Vienna

12:00 Developing a Highly Efficient Platform for TCR Identification in Solid Tumour Indications

To see full session details, download the full event guide

Felix Lorenz, Head, Captain T Cell

 

12:00 Examining Real-World Results in CD19 CAR-T in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

To see full session details, download the full event guide

Catherine Thieblemont, Head of Haemato-Oncology Department, Hôpital Saint-Louis

 

12:00 Considerations and Best Practice in
Delivering Cell Immunotherapies with a European Healthcare Authority

To see full session details, download the full event guide

Valeria Judkowski, Senior Director, Quality Assurance Head Site Qualification EU, Kite: A Gilead Company

 

12:30 Selection of True TCR Targets Using Humanised TCR Mice

To see full session details, download the full event guide

Elisa Kieback, CEO, T-Knife

 

12:30 Setting the Bar with Two Commercial CAR-T Products, and Next Steps for the Industry to Advance the Field

To see full session details, download the full event guide

Krishnan Viswanadhan, SVP, Global Cell Therapy Franchise Lead, Bristol Myers Squibb

12:30 Planning and Commercial Strategy for a Highly Innovative, Global Cell Therapy Pipeline

To see full session details, download the full event guide

Kelly Page, Head of Global Cell Therapy Commercialisation, Takeda Oncology

 

1:00 pm Lunchtime Poster Session

Innovations & Next-Generation CAR Technologies

Combination & Multi-Targeting Approaches for Enhanced Solid Tumour Efficacy

Commercial Strategy for Seamless Cell Immunotherapy Delivery in the EU

14:00 Breakthroughs in HIV Treatment with Dual CAR-T Using Lessons Learned from CAR-T for Oncology

To see full session details, download the full event guide

James Riley, Professor of Microbiology, University of Pennsylvania

 

14:00 Contrasting Checkpoint Inhibitors in Combination with CAR-T and as Engineered CARs for Optimal Solid Tumour Impact

To see full session details, download the full event guide

Blake Aftab, VP, Preclinical & Translational Science, Atara Biotherapeutics

 

14:00 Sharing Experience of Point-of-Care CAR T-Cell Production Using a Closed Semi-Automatic Bioreactor

To see full session details, download the full event guide

Maria Castellà, Production Manager, Immunotherapy Platform, Hopital Clinic-BST

14:30 Introducing DAR-T Technology for Improved Specificity and Safety, “Off-the-Shelf”

To see full session details, download the full event guide

Wenzhong Guo, CTO, Cell Therapy, Sorrento Therapeutics Inc

 

14.30 Heating Things Up: Combination Strategies to Access Cold Tumours

To see full session details, download the full event guide

Laurence Cooper, CEO, Ziopharm Oncology

 

14:30 Managing the Chain of Identity for Seamless, Patient-Centric Supply

To see full session details, download the full event guide

William Shingler, Senior Director, Patient & Cell Management, Autolus Ltd.

15:00 Next-Generation Gene Editing Technology for Allogeneic Immune Cell Therapeutics

To see full session details, download the full event guide

Steven Kanner, Chief Scientific Officer, Caribou Biosciences

 

15:00 Discussing Clinical Management and Outcomes in Delivering MultiTAA Therapy in Challenging Pancreatic Solid tumour Indications

To see full session details, download the full event guide

Mythili Koneru, CMO, Marker Therapeutics

 

15:00 Q&A with Your Expert Speakers

To see full session details, download the full event guide

Maria Castellà, Production Manager,
Immunotherapy Platform Hopital Clinic-BST

William Shingler, Senior Director, Patient & Cell Management, Autolus Ltd.

3:30 pm Chair’s Closing Remarks

3:45 pm End of Day 2